Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB...
SHANGHAI, Aug. 16, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Con...
* This investment will establish a cutting-edge, fully integrated CRDMO center inSingapore, inclu...
- The first GMP certificate that WuXi Vaccines has received from the regulatory agency - A critica...
SHANGHAI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- WuXi XDC, a global leading CRDMO (Con...
* WuXi Biologics expands its extensive integrated CRDMO services by offering development and cGMP...
* WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services f...
- WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goa...
SINGAPORE, April 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract ...
Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million G...
SHANGHAI, March 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO serv...
SHANGHAI, March 1, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO servi...
SHANGHAI, Feb. 8, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department...
* WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier ...
* Enhances drug product services for projects at various stages, with an emphasis on late and com...
- Successfully completed nearly 20 regulatory inspections in total, including 13 regulatory inspect...
* Successfully completed 12 regulatory inspections so far this year WUXI, China, Sept. 1, 2021 /P...
* Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million * Gross Profit Grows by 191.7% Y-o-Y t...
SUZHOU, China, Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company...
* First GMP manufacturing authorization outside of China, validating WuXi Biologics' world-class ...
